Page last updated: 2024-11-13
bottromycin a(2)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bottromycin A(2): from streptomyces; specific inhibitor to protein sythesinin the in vivo & in vitro bacterial systems; structure; see also record for bottromycin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 25215756 |
| CHEMBL ID | 1256112 |
| SCHEMBL ID | 13383277 |
| MeSH ID | M0059116 |
Synonyms (7)
| Synonym |
|---|
| bottromycin a(2) |
| 15005-62-6 |
| bottromycin a2 |
| CHEMBL1256112 |
| SCHEMBL13383277 |
| DTXSID701028185 |
| AKOS040755423 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID517669 | Antimicrobial activity against Enterococcus faecium NCTC 12201 by standard serial-dilution technique | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| AID517668 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus 92-1191 by standard serial-dilution technique | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| AID517670 | Antimicrobial activity against Enterococcus faecium NCTC 12203 by standard serial-dilution technique | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| AID517666 | Antimicrobial activity against Staphylococcus aureus Smith by standard serial-dilution technique | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| AID517667 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus HH1 by standard serial-dilution technique | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| AID517671 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as rate of residual activity | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| AID517665 | Antimicrobial activity against Staphylococcus aureus FDA209P by standard serial-dilution technique | 2010 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20 | Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||